# Centro de Pesquisas Oncológicas

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/centro-de-pesquisas-oncologicas/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 36 |
| Citations | 32,096 |
| City | Florianópolis |
| Country | BR |
| Description | Centro de Pesquisas Oncológicas is a research organisation in Florianópolis, BR. OpenAlex records 2,676 works and 32,096 citations for it. 1,419 researchers list it as their most recent affiliation. |
| Homepage | https://www.cepon.org.br/ |
| OpenAlex ID | https://openalex.org/I4210163308 |
| Region | Santa Catarina |
| Researchers | 1,419 |
| ROR ID | https://ror.org/052dytr59 |
| Type | facility |
| Works | 2,676 |

## University papers

- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-placebo-plus-chemotherapy-for-her2/)
- [Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-chemotherapy-as-first-line-treatment-in/)
- [Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer](https://scholariq.org/papers/phase-iii-keynote-789-study-of-pemetrexed-and-platinum-with-or-without/)

## University top topics

Showing 8 of 17.

- [Women's cancer prevention and management](https://scholariq.org/topics/women-s-cancer-prevention-and-management/)
- [Palliative and Oncologic Care](https://scholariq.org/topics/palliative-and-oncologic-care/)
- [Health, Nursing, Elderly Care](https://scholariq.org/topics/health-nursing-elderly-care/)
- [Healthcare during COVID-19 Pandemic](https://scholariq.org/topics/healthcare-during-covid-19-pandemic/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Public Health in Brazil](https://scholariq.org/topics/public-health-in-brazil/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.